Call Options

18 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$8.58 - $11.4 $168,168 - $223,440
-19,600 Reduced 22.9%
66,000 $741,000
Q3 2023

Nov 14, 2023

BUY
$8.38 - $10.44 $579,058 - $721,404
69,100 Added 418.79%
85,600 $738,000
Q2 2023

Aug 11, 2023

SELL
$10.16 - $11.92 $1.17 Million - $1.37 Million
-115,200 Reduced 87.47%
16,500 $170,000
Q1 2023

May 16, 2023

SELL
$9.87 - $11.44 $908,039 - $1.05 Million
-92,000 Reduced 41.13%
131,700 $1.43 Million
Q4 2022

Feb 14, 2023

BUY
$9.65 - $11.34 $1.2 Million - $1.41 Million
124,700 Added 125.96%
223,700 $2.51 Million
Q3 2022

Nov 14, 2022

BUY
$8.39 - $10.22 $91,451 - $111,398
10,900 Added 12.37%
99,000 $1 Million
Q2 2022

Aug 15, 2022

BUY
$8.41 - $10.34 $201,840 - $248,160
24,000 Added 37.44%
88,100 $798,000
Q1 2022

May 16, 2022

BUY
$8.33 - $12.96 $432,327 - $672,624
51,900 Added 425.41%
64,100 $613,000
Q4 2021

Feb 14, 2022

SELL
$7.42 - $11.05 $1.43 Million - $2.12 Million
-192,200 Reduced 94.03%
12,200 $135,000
Q3 2021

Nov 15, 2021

BUY
$6.77 - $14.41 $1.03 Million - $2.19 Million
152,000 Added 290.08%
204,400 $1.51 Million
Q2 2021

Aug 11, 2021

BUY
$14.52 - $22.46 $142,296 - $220,108
9,800 Added 23.0%
52,400 $761,000
Q1 2021

May 17, 2021

BUY
$16.57 - $21.08 $268,434 - $341,496
16,200 Added 61.36%
42,600 $869,000
Q3 2020

Nov 16, 2020

SELL
$14.79 - $22.49 $211,497 - $321,607
-14,300 Reduced 35.14%
26,400 $390,000
Q1 2020

May 15, 2020

BUY
$17.84 - $31.21 $349,664 - $611,716
19,600 Added 92.89%
40,700 $941,000
Q2 2019

Aug 14, 2019

BUY
$15.6 - $25.15 $177,840 - $286,710
11,400 Added 117.53%
21,100 $345,000
Q1 2019

May 15, 2019

BUY
$22.57 - $28.15 $4,514 - $5,630
200 Added 2.11%
9,700 $220,000
Q4 2018

Feb 14, 2019

SELL
$22.52 - $35.07 $45,040 - $70,140
-2,000 Reduced 17.39%
9,500 $243,000
Q3 2018

Nov 14, 2018

BUY
$22.83 - $32.67 $262,545 - $375,705
11,500 New
11,500 $376,000

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $636M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.